

# The Need for a Diagnostic Instrument to Assess Post-Traumatic Stress Disorder in People with Dementia: Findings from a Delphi Study

Journal of Geriatric Psychiatry  
and Neurology  
2023, Vol. 36(2) 129–142  
© The Author(s) 2022



Article reuse guidelines:  
[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)  
DOI: 10.1177/08919887221103583  
[journals.sagepub.com/home/jgp](https://journals.sagepub.com/home/jgp)



Demi C.D. Havermans, MSc<sup>1,2</sup> , Sebastiaan P.J. van Alphen, Prof, MD, PhD<sup>2,3,4</sup>,  
Miranda Olff, Prof, MD, PhD<sup>5,6</sup>, Mariëlle Van der Velden-Daamen, MD, PhD<sup>7,8</sup>,  
Frans Verhey, Prof, MD, PhD<sup>1</sup>, Bart P.F. Rutten, Prof, MD, PhD<sup>1</sup>, Peggy Stuijts, MSc<sup>9</sup>,  
Joan M Cook, PhD<sup>10</sup>, and Sjacko Sobczak, MD PhD<sup>2,11</sup>

## Abstract

Cognitive and behavioral aspects may mask posttraumatic stress disorder (PTSD) in people with dementia. PTSD severely lowers quality of life in people with dementia. Proper recognition of PTSD is essential to ensure adequate treatment. However, a valid diagnostic tool for PTSD in dementia is lacking. A Delphi study was conducted among 20 Dutch and 6 international experts in the field of PTSD and dementia care or research. The aim was to reach consensus in 3 rounds on the added value, form, content, and application for developing such an instrument. The first round confirmed the need for a new diagnostic tool for research and clinical practice. Consensus was reached on 23 statements regarding the support base and 19 related to content of the instrument. In the third round, opinions on several conceptual problems were gathered. Based on the experts' opinions, a draft version of an instrument, the TRAuma and DEmentia-interview (TRADE-interview), was developed. Clinical and research implications of this new measure are discussed.

## Keywords

Delphi-design, post traumatic stress disorder, dementia, diagnostic questionnaire, older adults

<sup>1</sup>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Maastricht University Medical Centre+, Maastricht, The Netherlands

<sup>2</sup>Department of Old Age Psychiatry, Mondriaan Mental Health Center, Heerlen, The Netherlands

<sup>3</sup>Department of Clinical and Life Span Psychology, Vrije Universiteit Brussel (VUB), Brussels, Belgium

<sup>4</sup>Department of Medical and Clinical Psychology, School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands

<sup>5</sup>ARQ National Psychotrauma Centre, Diemen, The Netherlands

<sup>6</sup>Department of Psychiatry, Amsterdam Public Health, Amsterdam University Medical Centers Location AMC, Amsterdam, The Netherlands

<sup>7</sup>Department of Health Services Research, Maastricht University, Maastricht, The Netherlands

<sup>8</sup>Department of Psychogeriatrics, Cicero-Zorggroep, Brunssum, The Netherlands

<sup>9</sup>Meandergroep Zuid-Limburg, Heerlen, The Netherlands

<sup>10</sup>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

<sup>11</sup>Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands

## Corresponding Author:

Demi C.D. Havermans, MSc, Department of Old Age Psychiatry, Mondriaan Mental Health Center, Heerlen, The Netherlands. Kloosterkensweg 10, 6419PJ Heerlen.

Email: [d.havermans@maastrichtuniversity.nl](mailto:d.havermans@maastrichtuniversity.nl)

## Objective

Although posttraumatic stress disorder (PTSD) is a common psychiatric diagnosis in the general population (7-8%),<sup>1,2</sup> PTSD is not often diagnosed in older adults (1-3%).<sup>3,4</sup> Evidence has been accumulated for important links between PTSD and dementia,<sup>5-8</sup> with comorbidity rates of PTSD in people with dementia at 4.7-7.8%.<sup>9</sup> Globally, the number of patients with dementia is estimated to be 35.6 million in 2010 and will double almost every 20 years to approximately 115.4 million by 2050.<sup>10</sup> Based on the findings, affected patients with comorbid PTSD could be between 2.5-4.2 million (53.4\*4.7-7.8%) in 2020 and increasing to 5.4-9.0 million (53.4\*4.7-7.8%) in 2050. However, due to the lack of a structured diagnostic tool for PTSD in these patients, these are probably underestimates.<sup>4</sup> While the nature of the associations between dementia and PTSD is still unclear, several hypotheses about possible underlying mechanisms have been postulated.<sup>11-16</sup> For example, PTSD and dementia share many comorbidities (e.g., impairments in attention and memory, depression, substance abuse, cardiovascular diseases).<sup>17-19</sup>

A decrease in perceived quality of life is known in both dementia and PTSD.<sup>20,21</sup> It can therefore be assumed that the simultaneous occurrence of PTSD in people with cognitive impairment or dementia may further negatively affect the quality of life in many aspects. Dementia and PTSD are both common and place a significant burden on patients, family members and other caregivers. Pinciotti, Bass, McCarthy, Judge, Wilson, Morgan, Snow, Kunik<sup>22</sup> reported more difficult behavioral symptoms in people with dementia and comorbid PTSD than without PTSD, which also increased the burden on caregivers and, therefore, increase health care costs. Problem behavior can be a real challenge for informal caregivers and, in addition to dementia, has a huge impact on the quality of life of patients, relatives and others involved.<sup>20</sup> Better recognition of PTSD in people with dementia is essential to optimize personalized care to improve the quality of life and reduce problem behavior through less: intensive nursing care, medication, medical consultations, freedom-restricting or other coercive interventions.

Developments in the field are hampered by the current lack of a structured diagnostic tool for PTSD in individuals with dementia, which meets the standards of the classical test theory.<sup>23-25</sup> Clinical assessment, assessing for exposure to potentially traumatic events and current PTSD symptoms, seems to be the most common method.<sup>23,26-30</sup> Instruments that have been most often used for assessing PTSD symptoms in those with dementia are: Impact of Event Scale-Revised (IES-R),<sup>31</sup> Post Traumatic Stress Screen for the Cognitively Impaired (PTSS-CI),<sup>24</sup> PTSD Checklist-Civilian Version (PCL-C),<sup>32</sup> Clinician-Administered PTSD Scale for DSM-V (CAPS-V)<sup>32,33</sup> and the Mini International Neuropsychiatric Interview (MINI).<sup>32</sup>

However, none of these instruments have been validated through the classical test theory in a population with dementia.<sup>24</sup> For example, they are based on self-report and/or anamnestic interviews, which are not conceivable in cognitively impaired populations.<sup>34</sup> Besides, these instruments often use complicated wording and response categories which are too complex for this population. Though the PTSS-CI was specifically developed for those with cognitive impairments, this screening instrument has not been validated through the classical test theory in older adults. The PTSS-CI is furthermore limited as it has been designed as a screening tool, and not a diagnostic instrument (which is the aim of the present study). Another important limitation in diagnosing PTSD in those with dementia is that published case reports show that most people with comorbid PTSD and dementia may not show enough symptoms to meet the criteria for a formal psychiatric diagnosis.<sup>23,26,30,32,35</sup> For example, avoidance symptoms were in most cases not expressed. Many older adults with dementia may live in long-term care facilities, and thus experience and expression of their avoidance may be different and not endorsed. Also, older adults may also not connect their current symptoms with their past traumatic experiences, or may have modified their lifestyle so that avoidance is automatic rather than effortful (e.g., systematically avoiding interactions with other people or only going out when they are unlikely to confront others).<sup>9</sup> Furthermore, behavioral expression of PTSD symptoms could be misinterpreted and classified as being part of the dementia syndrome such as Behavioral and Psychological Symptoms of Dementia (BPSD). For instance, re-experience symptoms occurring during the night may induce perception of danger and thereby to nightly wandering and be classified as BPSD.<sup>23,28,30</sup> In line with previous suggestions,<sup>23</sup> we have postulated that BPSD may also be linked to comorbid (yet undetected) PTSD, and that this link may be especially relevant in those with a delayed onset course.<sup>36</sup> Interestingly, thus far only one study reported higher levels of BPSD in people with dementia with comorbid PTSD compared to those without PTSD.<sup>22</sup> As PTSD, dementia, and BPSD all impact negatively on quality of life,<sup>37</sup> the combination may further decrease well-being. Thus, both in clinical practices as in research, there is a need for a structured method to diagnose PTSD in people with dementia. Recognition of PTSD can help health care practitioners give direction to management possibilities.<sup>23,38</sup> For example, personalized trauma-focused psychotherapy, namely Eye Movement Desensitization (EMDR), has been shown to relieve BPSD in those with severe dementia.<sup>30,39</sup>

In order to improve knowledge on PTSD in dementia, increase treatment possibilities, decrease health care burden, and improve the quality of life in those with dementia, we aimed to investigate the added value of a new instrument to diagnose PTSD in people with dementia among international experts, and to assess the optimal form, content, and application of such a measure. The current Delphi study is the

first initiative to develop such a diagnostic tool and its usability by using an international expert team.

## Method

The Delphi methodology (i.e., soliciting opinions of experts through a series of questionnaires together with information and opinion feedback with the aim to establish convergence of opinion) was used for the present study. This method is most often employed when there is little to no empirical evidence or clinical consensus on the topic of interest.<sup>40,41</sup> A Delphi design was used to reach consensus about statements with experts in PTSD and/or dementia. The survey rounds addressed: 1) the need for a structured method to assess PTSD in dementia, and whether current instruments might already be sufficient; 2) which domains and items should be included in the new instrument (TRAuma and DEmentia-interview; the TRADE-interview); and 3) scoring of items, diagnosis criteria, and severity measurement.

The first round specifically evaluated the need for a screener, a diagnostic tool, and a severity measurement (see Table 1). A **screening tool** is an instrument that can quickly indicate whether a certain disorder is present and distinguishes those who are eligible for a more detailed assessment from those who would not benefit from it. A **diagnostic tool** is used to check whether the criteria are met to make a certain diagnosis, while the **severity measurement** is used to investigate how much impact a disorder has on an individual (see below Table 1).

## Recruitment of Experts

The international and national experts were selected through: (1) an online search of relevant peer-reviewed publications on PTSD (i.e., in older adults) and/or BPSD and dementia; (2) consultation of national associations such as ‘Nederlandstalige Vereniging voor Psychotrauma’ (NtVp) and the Dutch association of specialists in geriatric medicine ‘Verenso’; (3) approaching international associations for trauma (see Supplemental Appendix 1); and (4) asking each expert was asked to nominate other specialists who could serve as participants in the study.

The expert group consisted of psychologists, behavioral scientists, medical doctors all working in the field of psychiatry and/or geriatric care who met the following criteria: (1) had at least five years of clinical, research, educational, diagnostic or treatment experience with PTSD (trauma expert) or in the field of people with dementia (dementia expert); and (2) had an identifiable affinity with diagnostics, older adults and/or dementia when they were trauma expert, or they had an identifiable affinity with stress, PTSD, BPSD when they were dementia expert.

## Procedure

The Delphi study’s statements were compiled through a literature search and supplemented with the research teams’ clinical and academic experiences (D.H., S.S., M.v.d.V., S.v.A., F.V. & B.R.). Each topic was briefly introduced (e.g., elements, main criteria, and sub-criteria), after which the experts were asked to indicate a level of agreement with each statement using a five-point Likert scale (i.e., Strongly agree, Agree, Neither agree nor disagree, Disagree or Strongly disagree). Responses of ‘Strongly agree’ and ‘Agree’ were grouped and categorized as agreement. The responses of ‘Disagree’ and ‘Strongly disagree’ were grouped and categorized as disagreement. Consensus was achieved when at least 66,7% agreed with a statement (strongly agree and somewhat agree).<sup>42</sup> Participants were given a chance to elaborate or express their opinion on the free-response comments. The results of the last part of round 3 were not designed to gain consensus, but rather to increase depth of experts’ opinion. After each round, results were analysed and assessed in Microsoft Excel and implemented in the following round. Findings were discussed with the research team. Between the rounds, participants were provided a summary of the panel’s responses.

Between May and June 2020, experts received 3 questionnaires via Qualtrics, an online survey software tool that facilitates design and conducts online questionnaires. Experts were given 5 working days to reply in each round. If a participant did not respond after five days, they were excluded from the further rounds. The experts were reminded twice during these 5 working days through e-mail to complete the round. The average length of time between rounds was 5 to ten days.

Approval for this study was obtained from the Ethics Review Committee Psychology and Neuroscience (ERCPN) of the University of Maastricht. Before starting the study, an information letter was sent to the potential participants regarding the study’s aims, purpose, and requirements for participation. The participants were informed that the study was voluntary and that they had the right to drop out of the study at any time. Completion of the survey was deemed as consent.

Data were collected digitally using Qualtrics research software and were exported to Microsoft Excel for statistical analysis. The consensus was calculated for each statement using frequency, mean, and standard deviation formulas.

## Results

A flow chart summarizing each round of the Delphi study and panel characteristics is shown in Figure 1. The

**Table 1.** Agreement ratings regarding the support base, existing tools, and care settings.

<u>Statement: The new instrument should be a:</u>	<u>Screening tool</u>	<u>Diagnostic tool</u>	<u>Severity measurement</u>
<b>Support base and existing tool</b>			
Need in clinical practice	88%	81%	77%
Need in the area of research	96%	92%	88%
Need for improving treatment	96%	92%	Not applicable
Need for understanding behaviour	96%	96%	73%
Need for diagnosing PTSD earlier	88%	85%	Not applicable
LEC-5	42%	Not applicable	Not applicable
GPS	23%	Not applicable	Not applicable
CTES/RTES	27%	Not applicable	Not applicable
CAPS-5	Not applicable	23%	27%
PDS-5	Not applicable	23%	Not applicable
PTSS-CI	Not applicable	65%	Not applicable
PCL	Not applicable	39%	46%
PSS-SR-5	Not applicable	Not applicable	27%
<b>Care settings</b>			
Primary care	73%	65%	54%
Specialist mental health care	96%	92%	96%
Nursing homes	92%	85%	81%
Hospital	77%	65%	50%


Note: green (consensus; >67%), orange (consensus; 67%), red (no consensus; <67%), and white (not applicable)

appendix contains an extensive table with the results. Based on the experts' opinions, a draft version of the TRADE-interview has been developed.

### Support Base

Consensus was reached for developing a new instrument for the screener, the PTSD diagnostic, and the severity measurement of PTSD (see Table 1). No consensus was reached (agreement rating of 58%) on the item 'diagnosing PTSD in people with dementia is sufficiently reliable based on only

clinical research', with experts indicating that this item was not relevant and unclear. Given the lack of consensus on this item, it was decided to drop this item. In addition, no consensus was reached on suitability of existing tools to screen and diagnose PTSD in people with dementia (agreement ratings ranging from 23% - 65%, see Table 1). The experts agreed that a new instrument should not be too extensive, use simple language, not use Likert scale, and primarily adhere to the Diagnostic and Statistical Manual for Mental Disorders-Fifth Edition (DSM-5) criteria. All previously mentioned instruments did not meet these criteria except for the



**Figure 1.** Summary Delphi study and panel characteristics.

PTSS-CI, which nearly reached consensus (65%). However, the PTSS-CI needs further evidence to establish the reliability and validity in older adults and is only a screening instrument. The experts clearly stated that the PTSS-CI could be used as an example regarding language, length, and the objective part, which all fit with this target group.

The last part of round one was related to which health care disciplines the development of a new tool for screening, diagnosing, and measuring severity could be relevant (see Table 1). Consensus was reached for psychologists and doctors being able to conduct the TRADE-interview (agreement ratings ranging from 81-100%). In addition, the experts agreed that ideally, the instrument should contain both a screener for traumatic life events, diagnostics for PTSD and a severity measurement (agreement ratings ranging from 77-100%). Finally, we posed the question to the expert panel for which clinical picture they think the instrument is no longer useful for. The experts agreed that severe language problems (comprehension problems), severe dementia, and not being able to respond to his/her surroundings are exclusion criteria for using the instrument.

### Content of the TRADE-Interview

Round 2 was related to which elements should be included in the new instrument according to the expert panel. Consensus was reached to include the anamnesis, informant information, clinical observation, and file study in the TRADE-interview (agreement ratings ranging from 76%-86%) (see Table 2). No consensus was achieved to include physiological measures to assess increased physiological

reactivity for trauma-related signals (e.g., heart rate, blood pressure) (33%) (Table 2). Consensus was reached on including all the DSM-5 main criteria for PTSD (e.g., avoidance symptoms, mood symptoms).<sup>43</sup> However, consensus was not reached on some of the sub-criteria, as these were regarded as non-specific and could also be symptoms of BPSD or related to ageing (e.g., difficulty concentrating, physical activity after trauma reminder; see Table 3). Fifteen of the 24 sub-criteria from DSM-5 reached consensus and were included in the new instrument. As a result, 12 out of 15 sub-criteria were included in the anamnesis, 14 sub-criteria in the informant information, and nine sub-criteria were selected for the clinical observation. Furthermore, none of the 'other symptoms' (i.e., psychiatric symptoms that often occur in people with PTSD but cannot be classified) achieved consensus. In round 3, the experts were asked if the 'other symptoms' would be of added value to screen for PTSD, but it was often commented that these symptoms could also have many other causes and could not definitively be distinguished for PTSD. Therefore, none of the 'other symptoms' were included in the new instrument (e.g., wandering, screaming; see Table 3).

### Conceptual Issues

Round 3 consisted of several application issues regarding the implementation of the new instrument. For the last part of this round, the aim was to consider experts' opinions and not necessarily reach consensus. This option was chosen because many options were possible, and a decision can only be made once this new tool has been tested in practice.



**Table 2.** Agreement ratings regarding the elements.

Statement	Agree	Neutral	Disagree
Anamnesis	76%	10%	14%
Informant information	86%	0%	14%
Clinical observation	81%	14%	5%
Physiological measures	33%	19%	48%
File study	81%	5%	14%

Note: green (consensus; >67%), orange (consensus; 67%), red (no consensus; <67%), and white (not applicable)

For this study, we chose the answer with the highest consensus achieved to be reviewed. The first question was about scoring the items. There were various response options (see Table 4). 76% of the experts indicated that an item or sub-criterion is met if one or 2 of the 3 elements (anamnesis, informant information, and clinical observation) are scored 'yes'. When 'yes' is scored, this means that the sub-criterion is met for this element (e.g., anamnesis, informant information, clinical observation). It, therefore, makes no difference if there is an overlap between symptoms from the anamnesis, informant information, and/or clinical observation.

The second application issue was about how the new instrument can be used to diagnose PTSD, because in round 2 the experts indicated that nine sub-criteria of PTSD were excluded. The experts had very different answers to this question. There was no clear majority in any option, but most indicated that the diagnosis should be made based on a certain number of sub-criteria (29%) or chose the option 'other' (29%). Most indicated that before such cut-offs should and could be considered, we must await actual testing and observation. The third application issue contained the question of how the severity measurement would be determined at the observation part and at the end of the new instrument. No severity scale is added to the anamnesis and hetero anamnesis because the experts indicated several times that it is complicated for people with dementia and their relatives or friends to indicate severity reliably. Most of the experts chose the 'other' option, indicating that the severity should be assessed by determining how the symptoms impair function on a zero to 2 scale (41%). Moreover, 35% indicated that the severity should be assessed by the interviewer based on frequency and suffering.

## Discussion

The main goal of the present study was to reach consensus among international experts about the added value of a new instrument to diagnose PTSD in people with dementia, as

well as the form, content, and application of such a measure. This study is the first in addressing the need and requirements for a new instrument aimed at PTSD in those with dementia where the focus was on both diagnosis and severity, used simple language, adhered to DSM-5 criteria, and was not too long. The experts agreed on the need for this new instrument (TRAuma and Dementia-interview; TRADE-interview).<sup>23,24,44</sup>

In 3 rounds of discussions experts concluded that the 'other symptoms' and several sub-criteria (e.g., flashbacks, irritability, hyper-vigilance) should not be included because these were not specific for PTSD and could also be symptoms of BPSD or related to ageing.<sup>22,23,45</sup> However, clinical presentations show that 'other symptoms', such as memory problems, screaming, and wandering are often described in those with dementia and PTSD.<sup>26,27,30</sup> Thus, we suggest that the presence of 'other symptoms' can be used as an indicator for conducting the TRADE-interview. This also applies to the 'physiological measurements', for which several studies have shown that increased physiological reactivity related to trauma-related triggers is an excellent indication of a PTSD diagnosis.<sup>46,47</sup> Much is still unknown about the 'other symptoms' and the 'physiological measurements'. It is possible that in the future, more knowledge about those aspects will become available and could be useful for future practical applications of the TRADE-interview. Further, especially for people with advanced dementia, these data could be valuable because the anamnesis is then even more limited.

At the end of the study, suggestions for application were made. Concerning the scoring of the items it was decided that 'yes' to at least one of the 3 components should be answered to meet a PTSD sub-criterion for the highest reliability.<sup>45,48</sup> Regarding the diagnosis of PTSD, it was decided that one sub-criterion for the main criteria A (trauma), B (intrusion), and E (arousal symptoms) must be met to receive a diagnosis. The DSM-5 shows that these were the main essential criteria in cognitively impaired patients.<sup>43</sup> This can be explained by case reports in the literature that indicate that criterion C (avoidance

**Table 3.** Agreement ratings regarding sub-criteria and other symptoms.

Statement	Included	Anamnesis	Informant information	Observation	File study
<b>Trauma, actual or threatened violent death, serious injury or accident, or sexual violence</b>					
A1: Direct exposure	100%	85%	80%	-	80%
A2: Witnessing the trauma	80%	75%	75%	-	75%
A3: Learning that a relative or close friend was exposed to a trauma	40%	-	-	-	-
A4: Indirect exposure to aversive details of the trauma, usually in the course of professional duties	75%	67%	80%	-	73%
<b>Intrusion symptoms</b>					
B1: Unwanted upsetting memories	100%	89%	67%	58%	-
B2: Nightmares	100%	74%	79%	68%	-
B3: Flashbacks	95%	83%	83%	67%	-
B4: Emotional distress after exposure to traumatic reminders	60%	-	-	-	-
B5: Physical reactivity after exposure to traumatic reminders	55%	-	-	-	-
<b>Avoidance symptoms</b>					
C1: Avoidance of trauma-related thoughts or feelings	60%	-	-	-	-
C2: Avoidance of trauma-related external reminders	80%	73%	73%	80%	-
<b>Negative cognition and mood symptoms</b>					
D1: Inability to recall key features of the trauma	40%	-	-	-	-

D2: Overly negative thoughts and assumptions about oneself or the world	80%	80%	67%	60%	-
D3: Exaggerated blame of self or others for causing the trauma	80%	87%	67%	53%	-
D4: Negative affect	90%	76%	88%	82%	-
D5: Decreased interest in activities	55%	-	-	-	-
D6: Feeling isolated	60%	-	-	-	-
D7: Persistent loss of positive emotions	50%	-	-	-	-
<b>Alterations in arousal and reactivity</b>					
E1: Irritability or aggression	90%	71%	76%	82%	-
E2: Reckless or self-destructive behavior	70%	54%	69%	92%	-
E3: Hypervigilance	85%	44%	69%	94%	-
E4: Heightened startle reaction	85%	56%	75%	88%	-
E5: Difficulty concentrating	60%	-	-	-	-
E6: Difficulty sleeping	95%	72%	78%	78%	-
<b>Other symptoms</b>					
Resistance against caregivers	40%	-	-	-	-
Inappropriate dressing and undressing	10%	-	-	-	-
Bizarre eating habits	20%	-	-	-	-
Screaming	60%	-	-	-	-
Impaired problem-solving	0%	-	-	-	-
Impaired visuospatial skills	0%	-	-	-	-
Psychomotor retardation	0%	-	-	-	-
Delirium	10%	-	-	-	-
Memory problems	20%	-	-	-	-
Impaired scanning speed	0%	-	-	-	-
Wandering	30%	-	-	-	-
Disorientation	25%	-	-	-	-
Claiming behavior	30%	-	-	-	-
Addiction problems	40%	-	-	-	-
Self-mutilation	40%	-	-	-	-

Note: green (consensus; >67%), orange (consensus; 67%), red (no consensus; <67%), and white (not applicable)



**Table 4.** Conceptual issues regarding the implementation of the new instrument.

Statements	Percentage	Remarks
<b>Scoring of the items</b>		
Someone meets a criterion when answering 'yes' to the anamnesis	0%	
Someone meets a criterion when answering 'yes' to the informant information	0%	
Someone meets a criterion when answering 'yes' on the observation	0%	
Someone meets a criterion when 'yes' is answered based on the anamnesis, informant information, and observation	12%	-It depends on the reliability of the patient and the third person
Someone meets a criterion when 'yes' is answered based on the anamnesis and informant information	6%	-Clinicians will not be able to observe most of the items directly
Someone meets a criterion when 'yes' is answered based on the anamnesis and observation	0%	
Someone meets a criterion when 'yes' is answered based on the informant information and observation	6%	-Depends on the stage of dementia. In advances stages you will have to rely on the informant information and observation
Other:	76%	-To be completely sure -All three are equally important -38% indicated that 'yes' needs to be answered on 2 out of the 3 -31% indicated that 'yes' needs to be answered on 1 out of the 3
<b>Diagnosing PTSD</b>		

When someone meets the full criteria for DSM-5	18%	<p>-This must be more feasible in the TRADE-interview because the criteria will be measured through anamnesis, informant information, and observation</p> <p>-Do not give a diagnosis when less than full criteria are met. That is what the anxiety nos/subthreshold PTSD diagnosis is for</p>
When someone meets 1-3 criteria following DSM-5	24%	-Criteria A,B,E most clear criteria for cognitively impaired patients
When someone meets a number of sub-criteria	29%	<p>-At least 1 sub-criterion of each of the three main criteria (trauma, intrusion, and arousal)</p> <p>-1 sub-criterion for each main criterion, because the threshold should be low.</p> <p>-3 or more sub-criteria</p>
Other:	29%	<p>-Orient the diagnosis to ICD-11</p> <p>-Before such cut-offs should/could be considered, we must await actual testing and observation</p> <p>-Subsyndromal PTSD is clinically significant, and these criteria typically means missing a symptom or two (while still representing all main criteria of PTSD)</p>
<b>Severity measurement</b>		
The severity depends on the amount of main criteria someone meets (A-E)	0%	
The severity depends on the amount of sub-criteria someone meets	12%	

The severity is assessed using Likert Scale (frequency, severity, functioning)	12%	-The ability of the patient to answer the questions on Likert Scale is not always clear-cut  -Combine the frequency and intensity to get severity scores for each symptom, then the sum of these indicates overall severity
The severity is assessed by the interviewer based on frequency and suffering	35%	-Observe their frequency and impairment in functioning (as in the NPI)  -This option describes a kind of 'clinical view' and more objectively than that you will not get the severity 'measured'.
Other:	41%	-Assess, for each main criterion, the extent to which the symptoms impair function on a 0-2 scale (same as CAPS)

Note: green (consensus; >67%), orange (consensus; 67%), red (no consensus; <67%), and white (not applicable)

symptoms) were rarely reported.<sup>23,49</sup> Notably, most sub-criteria of criterion D (negative cognition and mood symptoms) were excluded in the TRADE-interview because they are indistinguishable from BPSD. Most experts indicated that before such cut-offs should and could be considered, actual testing and observation in practice should take place. When validating the instrument, it can be examined whether this is feasible or needs to be adjusted.

Although this study used the DSM-5 criteria to identify PTSD in people with dementia, ICD-11 should also be under consideration. The DSM-5 includes 20 symptoms, while the proposed ICD-11 criteria include only 6 qualifying symptoms for a more focused approach.<sup>50</sup> The ICD-11 has a unique way to identify PTSD avoiding overshadowing other disorders such as depression.<sup>51</sup> As a result, it could be expected that people with dementia, who are known to show less PTSD symptoms, are more likely to meet the diagnosis according to the ICD-11 compared to the DSM-5. However, a study from Fox, Hyland, McHugh Power, Coogan<sup>52</sup> found more older adults met the diagnostic criteria of PTSD based on the guidelines of the DSM-5 compared to the ICD-11. A shared limitation in diagnosing PTSD using the ICD-11 and DSM-5 is the required presence of one of the core elements 'avoidance symptoms', which a literature review show are not recognized in people with dementia.<sup>23,49</sup>

The development of the TRADE-interview has added value for both clinical practice and research. The TRADE-interview offers opportunities to conduct methodologically solid and consistent research into this complex target group. Clinically, this instrument can help in evaluating the indication for trauma-focussed therapy, such as EMDR and Prolonged Exposure therapy. Furthermore, the TRADE-interview can possibly differentiate potentially undiscovered PTSD in BPSD. In addition, more insight can be gained into the magnitude of the problem and about the occurrence of the impact of the PTSD symptoms in those with dementia. In future investigations, the TRADE-interview should be tested to assess its psychometric properties using classical test theory (i.e., diagnostic accuracy).<sup>25</sup> In addition, we hope to be able to investigate for which stages of dementia the instrument is suitable and possibly work towards an instrument that is useful for multiple stages of dementia. But most importantly, the first steps are made to improve diagnosing PTSD in people with dementia.

The primary limitations of this study were on the composition of the expert group which might have affected the finding. That is, the contribution of international experts ( $n = 4$ , 24%) was low compared to the Dutch experts ( $n = 13$ , 76%). However, as the opinions of international experts were overall in agreement with Dutch experts, that

information bias is likely low. It is notable that 65% of the experts were psychologists, with the remaining psychiatrists (5%), geriatric physicians (18%) and other (12%). It was also a challenge to include experts who were experienced in the field of both dementia and PTSD. Nevertheless, 60% of the psychologists were experts on working with PTSD in the older population. Thus, the current composition of the expert panel seemed well-suited for the development of the TRADE-interview. It may be that the composition of the expert team was also influenced by the COVID-19 crisis, as the start of the study was scheduled in March 2020, which was in the early stages of the pandemic. The study had to be postponed to May, though there were a few participants ( $n = 6$ ) who had withdrawn before starting due to the crisis. Another limitation of the current study is the use of the DSM-5 rather than looking into both DSM-5 and ICD-11. The ICD-11 has been included in the discussion, but in future it is important that the new instrument will also be translated to the ICD-11 guidelines. In addition, the expert panel decided to exclude some sub-criteria in the new instrument. This ensures that the symptoms are more specific to PTSD rather than explaining the dementia or other psychiatric diagnosis. However, with this we also risk missing symptoms, and this will therefore have to be investigated through the classical test theory (i.e., diagnostic accuracy) in further research.

The study results confirm the need for a diagnostic tool for PTSD in dementia patients for both scientific research and clinical practice. In accordance, with help of an international expert panel, we developed the TRADE-interview, which can be applied by health care professionals, particularly psychologists and doctors in primary care, specialist mental health care, nursing homes, and hospitals. In order to improve care of people with dementia with PTSD there are still multiple challenges beginning with testing its psychometric properties using classical test theory (i.e., diagnostic accuracy). Developing this tool may be the first step in discovering the impact of potentially traumatic life events in people with dementia and may hopefully lead to further initiatives to improve their care, treatment, and research.

### Author Contributions

All authors contributed to the design of the various Delphi rounds, interpretation of results, reviewed and critically revised the article, and approved the final version for submission. After the study, D. Havermans, S. Sobczak, P. Stuijts and M. Olff were involved in developing the TRADE-interview.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study received a grant by EMDR-Europe (2019-04) and is partially sponsored by University Fund Limburg (SWOL).

### Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

### ORCID iD

Demi C.D. Havermans  <https://orcid.org/0000-0001-8815-6541>

### Supplemental Material

Supplemental material for this article is available online.

### References

1. de Vries GJ, Olff M. The lifetime prevalence of traumatic events and posttraumatic stress disorder in the Netherlands. *J Trauma Stress*. 2009;22(4):259-267.
2. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. Trauma and PTSD in the WHO world mental health surveys. *Eur J Psychotraumatol*. 2017;8(sup5):1353383.
3. Reynolds K, Pietrzak RH, El-Gabalawy R, Mackenzie CS, Sareen J. Prevalence of psychiatric disorders in US older adults: findings from a nationally representative survey. *World Psychiatry*. 2015;14(1):74-81.
4. Sobczak S, Olff M, Rutten B, Verhey F, Deckers K. Comorbidity rates of Posttraumatic stress disorder in dementia: a systematic literature review. *Eur J Psychotraumatol*. 2021; 12(1):1883923.
5. Qureshi SU, Kimbrell T, Pyne JM, et al. Greater prevalence and incidence of dementia in older veterans with posttraumatic stress disorder. *J Am Geriatr Soc*. 2010;58(9):1627-1633.
6. Desmarais P, Weidman D, Wassef A, et al. The interplay between post-traumatic stress disorder and dementia: A systematic review. *Am J Geriatr Psychiatry*. 2020;28(1):48-60.
7. Yaffe K, Vittinghoff E, Lindquist K, et al. Posttraumatic stress disorder and risk of dementia among US veterans. *Arch Gen Psychiatry*. 2010;67(6):608-613.
8. Gunak MM, Billings J, Carratu E, Marchant NL, Favarato G, Orgeta V. Post-traumatic stress disorder as a risk factor for dementia: systematic review and meta-analysis. *Br J Psychiatry*. 2020;217(5):600-608.
9. Thorp SR, Sones HM, Cook JM. Posttraumatic stress disorder among older adults. *Cognitive behavior therapy with older adults: Innovations across care settings*. Springer Publishing Company; 2011:189-217.
10. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimer's & Dementia*. 2013;9(1):63-75. e62.

11. Khouzam HR. Posttraumatic stress disorder and aging. *Postgrad Med*. 2008;120(3):122-129.
12. McEwen B S. The brain on stress: Toward an integrative approach to brain, body and behavior. *Perspect Psychol SciNov*. 2013;1(6):673-675.
13. Lohr JB, Palmer BW, Eidt CA, et al. Is post-traumatic stress disorder associated with premature senescence? a review of the literature. *Am J Geriatr Psychiatry*. 2015;23(7):709-725.
14. Rutten BPF, Vermetten E, Vinkers CH, et al. Longitudinal analyses of the DNA methylome in deployed military servicemen identify susceptibility loci for post-traumatic stress disorder. *Mol Psychiatry*. 2018;23(5):1145-1156.
15. Wang TY, Wei HT, Liou YJ, et al. Risk for developing dementia among patients with posttraumatic stress disorder: A nationwide longitudinal study. *J Affect Disord*. 2016;205:306-310.
16. Miller MW, Lin AP, Wolf EJ, Miller DR. Oxidative stress, inflammation, and neuroprogression in chronic PTSD. *Harv Rev Psychiatry*. 2017;26:1-13.
17. Clemens V, Huber-Lang M, Plener PL, Brahler E, Brown RC, Fegert JM. Association of child maltreatment subtypes and long-term physical health in a German representative sample. *Eur J Psychotraumatol*. 2018;9(1):1510278.
18. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Psychiatric comorbidity of full and partial posttraumatic stress disorder among older adults in the United States: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *Am J Geriatr Psychiatry*. 2012;20(5):380-390.
19. Chopra MP, Zhang H, Pless Kaiser A, et al. PTSD is a chronic, fluctuating disorder affecting the mental quality of life in older adults. *Am J Geriatr Psychiatry*. 2014;22(1):86-97.
20. van Zelst WH, de Beurs E, Beekman AT, van Dyck R, Deeg DD. Well-being, physical functioning, and use of health services in the elderly with PTSD and subthreshold PTSD. *Int J Geriatr Psychiatry*. 2006;21(2):180-188.
21. Meléndez JC, Satorres E, Redondo R, Escudero J, Pitarque A. Wellbeing, resilience, and coping: are there differences between healthy older adults, adults with mild cognitive impairment, and adults with Alzheimer-type dementia? *Arch Gerontol Geriatr*. 2018;77:38-43.
22. Pinciotti CM, Bass DM, McCarthy CA, et al. Negative consequences of family caregiving for veterans with PTSD and dementia. *J Nerv Ment Dis*. 2017;205(2):106-111.
23. Martínez-Clavera C, James S, Bowditch E, Kuruvilla T. Delayed-onset post-traumatic stress disorder symptoms in dementia. *Progress in Neurology and Psychiatry*. 2017;21(3):26-31.
24. Carlson EB, Lauderdale S, Hawkins J, MDSheikh IJ. Posttraumatic stress and aggression among veterans in long-term care. *J Geriatr Psychiatry Neurol*. 2008;21(1):61-71.
25. Himelfarb I. A primer on standardized testing: history, measurement, classical test theory, item response theory, and equating. *J Chiropr Educ* 2019;33(2):151-163.
26. Johnston D. A series of cases of dementia presenting with PTSD symptoms in world war II combat veterans. *J Am Geriatr Soc*. 2000;48(1):70-72.
27. Mittal D, Torres R, Abashidze A, Jimerson N. Worsening of post-traumatic stress disorder symptoms with cognitive decline: case series. *J Geriatr Psychiatry Neurol*. 2001;14(1):17-20.
28. van Achterberg ME, Rohrbach RM, Southwick SM. Emergency of PTSD in trauma survivors with dementia. *J Clin Psychiatry*. 2001;62(3):206-207.
29. Skočić M, Dujmović J., Jevtović S., Jakovljević M. Pre-morbid combat related PTSD in Huntington's disease: case report. *Psychiatr Danub*. 2010;22:286-288.
30. Amano T, Toichi M. Effectiveness of the on-the spot-EMDR method for the treatment of behavioral symptoms in patients with severe dementia. *J EMDR Pract Res*. 2014;8:50-65.
31. Dunham A, Mellor D, Rand E, McCabe M, Lewis M. Impact of disclosure of a dementia diagnosis on uptake of support services: a pilot study exploring a post-traumatic stress approach. *Dementia*. 2019;19(8):1471301219844659.
32. Duax JM, Waldron-Perrine B. Prolonged exposure therapy for a vietnam veteran with PTSD and early-stage dementia. *Cogn Behav Pract*. 2012;20:64-73. doi:10.1016/j.cbpra.2012.02.001
33. Bonnani L, Franciotti R., Martinotti G., et al. Post traumatic stress disorder heralding the onset of semantic fronto-temporal dementia. *Journal of Alzheimer's Disease*. 2018; 63:203-215.
34. Cook JM, O'Donnell C. Assessment and psychological treatment of posttraumatic stress disorder in older adults. *J Geriatr Psychiatry Neurol*. 2005;18(2):61-71.
35. Bruneau MA, Desmarais P, Pokrzywko K. Post-traumatic stress disorder mistaken for behavioural and psychological symptoms of dementia: case series and recommendations of care. *Psychogeriatrics*. 2020;20(5):754-759.
36. Busuttill W. Presentations and management of post traumatic stress disorder and the elderly: a need for investigation. *Int J Geriatr Psychiatry*. 2004;19:429-439.
37. Van Zelst WH, De Beurs E, Beekman AT, Van Dyck R, Deeg DD. Well-being, physical functioning, and use of health services in the elderly with PTSD and subthreshold PTSD. *Int J Geriatr Psychiatry*. 2006;21(2):180-188.
38. Cook J, Ruzek J, Cassidy E. Practical geriatrics: possible association of posttraumatic stress disorder with cognitive impairment among older adults. *Psychiatr Serv*. 2003;54: 1223-1225.
39. Van Der Wielen M, Robben H, Mark RE. The applicability and effect of EMDR in a patient with a mild stage of Alzheimer's disease. *J EMDR Pract Res*. 2019;13(1):51-60.
40. Wollersheim H. Beyond the evidence of guidelines. *Neth J Med*. 2009;67(2):39-40.

41. Linstone HA, Turoff M. *The delphi method*. Reading, MA: Addison-Wesley; 1975.
42. Sharkey SB, Sharples AY. An approach to consensus building using the Delphi technique: developing a learning resource in mental health. *Nurse Educ Today*. 2001;21(5):398-408.
43. Association AP. *Diagnostic and statistical manual of mental disorders (DSM-5®)*. Washington, D.C: American Psychiatric Pub; 2013.
44. Sorrell JM, Durham S. Meeting the mental health needs of the aging veteran population. *J Psychosoc Nurs Ment Health Serv*. 2011;49(1):22-25.
45. Moore SA. Cognitive abnormalities in posttraumatic stress disorder. *Curr Opin Psychiatry*. 2009;22(1):19-24.
46. Shalev AY, Rogel-Fuchs Y. Psychophysiology of the posttraumatic stress disorder: from sulfur fumes to behavioral genetics. *Psychosom Med*. 1993;55(5):413-423.
47. Orr Scott P. An overview of psycho-physiological studies of PTSD. *PTSD Res Q* 1994;5(1):1-7.
48. Letzter-Pouw S, Werner P. Correlates of intrusive memories and avoidance of memories of the Holocaust. *Isr J Psychiatry Relat Sci*. 2005;42(4):271-277.
49. van Dongen HE, Havermans DCD, Deckers K, Olff M, Verhey F, Sobczak S. A first insight in the clinical manifestation of posttraumatic stress disorder in dementia: a systematic literature review. *Psychogeriatrics (online)*. 2022. doi:[10.1111/psyg.12830](https://doi.org/10.1111/psyg.12830).
50. World Health Organization. ICD-11: International classification of diseases (11th revision); 2019.
51. Fox R, Hyland P, Power JM, Coogan AN. Patterns of comorbidity associated with ICD-11 PTSD among older adults in the United States. *Psychiatry Res*. 2020;290: 113171.
52. Fox R, Hyland P, McHugh Power J, Coogan AN. Post-traumatic stress disorder among older adults: a differential item functioning analysis of PTSD in ICD-11 and DSM-5. *Psychol Trauma*. 2020;12(7):799.